Adicet Bio stock rating initiated at Buy by H.C. Wainwright

Investing.com - H.C. Wainwright has initiated coverage on Adicet Bio Inc. (NASDAQ:ACET) with a Buy rating and a $4.00 price target, according to a research note released Wednesday. The stock, currently trading at $0.75 with a market cap of $62.2 million, shows potential upside according to InvestingPro analysis, which indicates the stock is currently undervalued.

The coverage initiation focuses on Adicet’s ADI-270, an armored CD70-targeted allogeneic gamma delta CAR-T cell therapy candidate incorporating a third-generation CAR design. This therapy is currently being evaluated in a Phase 1 trial for CD70+ cancers and has received FDA Fast Track Designation for treating metastatic/advanced clear cell renal cell carcinoma (ccRCC) in patients previously treated with immune checkpoint and VEGF inhibitors. InvestingPro data shows the company maintains a strong current ratio of 9.34, with more cash than debt on its balance sheet, providing runway for its clinical development programs.

H.C. Wainwright highlighted preclinical data showing ADI-270’s ability to maintain proliferation and cytotoxicity in immunosuppressive environments, as well as demonstrating greater cytotoxicity in CD70-low tumors compared to CAR αβ T cell references.

The research firm referenced Allogene Therapeutics’ (NASDAQ:ALLO) ALLO-316 data presented at ASCO 2025, which showed a 25% overall response rate in heavily pretreated ccRCC patients, with a 31% response rate in patients with CD70 TPS > 50%.

Preliminary data for ADI-270 in ccRCC is expected in the second half of 2025, with initial Phase 1 trial results slated for release by the end of 2025, which H.C. Wainwright described as a "partially risk-mitigated data catalyst" supporting their Buy rating. With analyst targets ranging from $4 to $8, investors seeking deeper insights can access comprehensive analysis and 12 additional ProTips through InvestingPro’s detailed research report.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.